Original Article
Effect of Theophylline on Sleep-Disordered Breathing in Heart Failure
N Engl J Med 1996; 335:562-567August 22, 1996
- Abstract
Background
Theophylline has been used to treat central apnea associated with Cheyne–Stokes respiration (periodic breathing). We studied the effect of short-term oral theophylline therapy on periodic breathing associated with stable heart failure due to systolic dysfunction.
Methods
Fifteen men with compensated heart failure (left ventricular ejection fraction, 45 percent or less) participated in the study. Their base-line polysomnograms showed periodic breathing, with more than 10 episodes of apnea and hypopnea per hour. In a double-blind crossover study, the patients received theophylline or placebo orally twice daily for five days, with one week of washout between the two periods.
Results
After five days of treatment, the mean (±SD) plasma theophylline concentration was 11±2 μg per milliliter. Theophylline therapy resulted in significant decreases in the number of episodes of apnea and hypopnea per hour (18±17, vs. 37±23 with placebo and 47±21 at base line; P<0.001), the number of episodes of central apnea per hour (6±14, vs. 26±21 and 26±20, respectively; P<0.001), and the percentage of total sleep time during which the arterial oxyhemoglobin saturation was less than 90 percent (6±11 percent, vs. 23±37 and 14±14 percent, respectively; P<0.04). There were no significant differences in the characteristics of sleep, the frequency of ventricular arrhythmias, daytime arterial-blood gas values, or the left ventricular ejection fraction during the base-line, placebo, and theophylline phases of the study.
Conclusions
In patients with stable heart failure, oral theophylline therapy reduced the number of episodes of apnea and hypopnea and the duration of arterial oxyhemoglobin desaturation during sleep.
Media in This Article
Table 1
Sleep-Disordered Breathing Events and Arterial-Blood Values at Base Line, during the Administration of Placebo, and during the Administration of Theophylline in 15 Patients with Heart Failure.Table 2
Characteristics of Sleep at Base Line, during the Administration of Placebo, and during the Administration of Theophylline.Article Activity
- Article
In most patients with the sleep apnea syndrome, episodes of apnea are due to obstruction of the upper airways (obstructive apnea). Application of nasal continuous positive airway pressure eliminates the obstruction and thus prevents associated arterial oxyhemoglobin desaturation. Uvulopalatoplasty has also been performed in patients with obstructive sleep-disordered breathing.
In contrast to obstructive apnea, central apnea is characterized by the absence of airflow due to inactivation of the inspiratory pump muscles. Episodes of central sleep apnea associated with Cheyne–Stokes respiration (periodic breathing) occur most commonly in association with severe heart failure and systolic dysfunction.1-4 In our previous systematic study of patients with stable heart failure, periodic breathing occurred in 45 percent of the patients.5 Periodic breathing can result in severe arterial oxyhemoglobin desaturation,1-5 which may further impair cardiovascular function. Unlike obstructive sleep apnea, central apnea may not be readily treatable with continuous positive airway pressure, and uvulopalatoplasty is not indicated.
In a preliminary study,4 we found that the administration of theophylline improved periodic breathing in three patients with heart failure and repeated episodes of central apnea. In the present, placebo-controlled study, we assessed the efficacy of theophylline in the treatment of periodic breathing and arterial oxyhemoglobin desaturation during sleep in patients with stable heart failure and left ventricular systolic dysfunction.
Methods
Fifteen men with stable, medically treated heart failure and systolic dysfunction (left ventricular ejection fraction, 45 percent or less) took part in the study. These patients were a subgroup of 42 patients with stable heart failure and left ventricular systolic dysfunction who had undergone polysomnographic studies to determine the prevalence of periodic breathing, as reported previously.5 Nineteen consecutive patients whose initial polysomnograms showed periodic breathing, with more than 10 episodes of apnea and hypopnea per hour, were asked to take part in the present study. Two of the patients did not return for further studies, and two died before randomization.
We evaluated all the patients to confirm that they were clinically stable (defined as having no change in signs or symptoms of heart failure within the previous four weeks) and receiving optimal therapy, with no change in medications within the previous four weeks. Medications included angiotensin-converting–enzyme inhibitors (in 13 patients), hydralazine (in 2), digoxin (in 11), isosorbide dinitrate (in 7), and furosemide (in all 15). Doses were adjusted according to the clinical status of each patient. The average daily dose was 91 mg for captopril, 17 mg for lisinopril, 28 mg for enalapril, 175 mg for hydralazine, 62 mg for isosorbide dinitrate, 0.182 mg for digoxin, and 74 mg for furosemide.
Exclusion criteria were unstable angina; unstable congestive heart failure; acute pulmonary edema; congenital heart disease; intrinsic pulmonary diseases, including interstitial lung disease and obstructive lung defects (ratio of predicted forced expiratory volume to forced vital capacity, <80 percent); intrinsic renal and liver disorders; untreated hypothyroidism or kyphoscoliosis; and use of morphine derivatives, benzodiazepines, or theophylline.
Study Protocol
After giving written informed consent, the patients received placebo or theophylline (Theo-Dur; average dose, 3.3 mg per kilogram of body weight; Key Pharmaceuticals, Kenilworth, N.J.) orally twice daily for five days, in a randomized, double-blind fashion. Crossover studies were performed after a one-week washout period. During the study, the patients were admitted to the hospital for cardiac monitoring. To maintain blinding, the patients were monitored during both the theophylline and the placebo phases of the study. The study cardiologists, who were not blinded, supervised the administration of theophylline and the cardiac monitoring. Since the initial polysomnographic studies had shown marked arterial oxyhemoglobin desaturation during sleep, the patients were given oxygen at night during the study to prevent desaturation. In the sleep laboratory, however, the studies were performed while the patients were breathing room air. No change in medication was allowed during hospitalization.
The following studies were performed initially and on day 5 after the initial administration of theophylline or placebo: polysomnography with nocturnal Holter monitoring, serum theophylline measurements, radionuclide ventriculography, arterial-blood gas and pH measurements, and pulmonary-function tests.
Polysomnography was performed with the use of standard techniques, as described previously.4-6 All the patients had been adapted to the sleep laboratory at the time of the initial evaluation. To determine the stages of sleep, we obtained an electroencephalogram (with two channels), chin electromyogram (one channel), and electro-oculogram (with two channels). Thoracoabdominal excursions were measured qualitatively by respiratory inductance plethysmography (Respitrace, Ambulatory Monitoring, Ardsley, N.Y.) or with pneumatic respiration transducers (Grass Instrument, Quincy, Mass.) placed over the rib cage and abdomen. Airflow was monitored qualitatively with an oronasal thermocouple (Model TCT1R, Grass Instrument). Arterial-blood oxyhemoglobin saturation was recorded with the use of an ear oximeter (Biox IIA, Bioximetry Technology, Boulder, Colo.). These variables were recorded on a multichannel polygraph (Model 78D, Grass Instrument).
An episode of apnea was defined as the cessation of inspiratory airflow for 10 seconds or more. An episode of obstructive apnea was defined as the absence of airflow in the presence of rib-cage and abdominal excursions. An episode of central apnea was defined as the absence of rib-cage and abdominal excursions and the absence of airflow.4-6 It should be noted, however, that without measurements of esophageal pressure, it is sometimes difficult to distinguish central from obstructive apnea. Hypopnea was defined as a reduction in airflow lasting 10 seconds or more and associated with at least a 4 percent decrease in arterial oxyhemoglobin saturation or an electroencephalographic arousal, or both. An electroencephalographic arousal was defined as the appearance of alpha waves on the electroencephalogram for at least three seconds.7 The number of episodes of apnea and hypopnea per hour is referred to as the apnea–hypopnea index. The polysomnograms were scored blindly.
To determine whether theophylline treatment was associated with the development of ventricular or supraventricular arrhythmias, Holter monitoring was performed during polysomnography. Three electrocardiographic channels (leads V1, V3, and V5) were recorded with the use of a Marquett Laser SxP Holter monitor system (Marquett Electronics, Milwaukee). The tapes were analyzed by computer and interpreted by a cardiologist.
Since theophylline is thought to improve cardiac function,8,9 right and left ventricular ejection fractions were calculated from gated first-pass and multigated radionuclide ventriculograms, respectively, with the use of standard techniques.
To determine the effect of theophylline on pulmonary function, we recorded lung volumes and flow rates,10 maximal inspiratory and expiratory pressures,11 and arterial-blood gas concentrations12 using strict criteria, as described previously.10-12 To minimize pain, 2 percent lidocaine was used to anesthetize the skin where the radial artery was punctured. By touching the skin with a needle, we assured the patients that the procedure was painless. Our intent was to minimize pain and anxiety and, thus, any attendant change in the arterial partial pressure of carbon dioxide.
Serum samples were obtained on days 2 and 5 during the theophylline and placebo phases of the study. Serum theophylline concentrations were measured by the colorimetric process, with the use of an Ekta-chem Analyzer 700 (Johnson and Johnson, Rochester, N.Y.).
Statistical Analysis
We used a two-way analysis of variance for repeated measures to compare variables during the base-line, placebo, and theophylline phases of the study. For paired comparisons, a two-tailed paired t-test with the Bonferroni correction was used. A P value of less than 0.025 was considered to indicate statistical significance. Values are reported as means ±SD. Calculations were made with the use of SAS software.13
Results
The 4 patients who were eligible but could not participate in the study had a mean apnea–hypopnea index of 40±11 and a mean left ventricular ejection fraction of 24±7 percent — values similar to those in the 15 patients who took part in the study.
Serum theophylline concentrations on day 5 ranged from 6.9 to 14.9 μg per milliliter, with a mean value of 11±2 μg per milliliter during the period when the patients were taking the drug. Theophylline was undetectable in serum during the placebo period and at base line.
The mean values for the study variables at base line and while the patients were receiving placebo or theophylline are shown in Table 1Table 1
Sleep-Disordered Breathing Events and Arterial-Blood Values at Base Line, during the Administration of Placebo, and during the Administration of Theophylline in 15 Patients with Heart Failure., Table 2Table 2Characteristics of Sleep at Base Line, during the Administration of Placebo, and during the Administration of Theophylline. and Table 3Table 3
Results of Spirometric Pulmonary-Function Tests at Base Line, during the Administration of Placebo, and during the Administration of Theophylline.. There were no significant differences in the characteristics of sleep, the numbers of episodes of sleep apnea and hypopnea, the values for arterial oxyhemoglobin desaturation, the values for arterial-blood gases and pH while the patients were awake, or the results of pulmonary-function tests at base line and during the placebo phase of the study.Stages of Sleep and Periodic Breathing
Treatment with theophylline resulted in a considerable reduction in periodic breathing and episodes of central apnea (Table 1). This reduction was associated with a significant improvement in the arterial oxyhemoglobin saturation during sleep, as reflected by a decrease in the total sleep time during which the saturation was less than 90 percent, as well as by an increase in the lowest saturation value during sleep (Table 1). There was also a decrease in the number of electroencephalographic arousals due to periodic breathing (Table 1).
Sleep stages, sleep efficiency (the ratio of the total sleep time to the total dark time), and the total number of arousals did not differ significantly among the three phases of the study (Table 2).
Pulmonary Function
Theophylline treatment significantly improved the forced vital capacity and forced expiratory volume in one second, although the ratio of forced expiratory volume in one second to forced vital capacity and the maximal respiratory pressures did not change significantly (Table 3). The mean values for arterial-blood gases and hydrogen ions while the patients were awake also did not change significantly (Table 1).
Cardiac Function and Rhythm
There were no significant differences in the right ventricular ejection fraction during the three study phases (50±14 percent at base line, 49±9 percent during the administration of placebo, and 48±12 percent during the administration of theophylline), nor were there significant differences in the left ventricular ejection fraction (26±10, 26±11, and 28±12 percent, respectively), the number of isolated premature ventricular depolarizations per hour of sleep (159±276, 189±357, and 240±307, respectively), the number of couplets per hour of sleep (6±8, 7±16, and 11±17, respectively), or the number of episodes of ventricular tachycardia (defined as three or more premature ventricular beats in a row) per hour of sleep (1±2, 1±2, and 1±3, respectively). Dizziness and supraventricular tachycardia developed in one patient on the third day of treatment with theophylline; the serum theophylline concentration was 8.6 μg per milliliter. Although we were not certain whether the administration of theophylline caused the tachycardia, treatment was stopped on the evening of day 3, and polysomnography was performed.
The men's mean body weight did not differ significantly among the three phases of the study (88.8±13.6 kg at base line, 88.1±14.1 kg during the administration of placebo, and 87.7±13.4 kg during the administration of theophylline). There was no significant correlation between changes in weight and the number of episodes of central apnea per hour.
Discussion
In this study, the short-term administration of oral theophylline improved sleep-disordered breathing and reduced associated arterial-blood oxyhemoglobin desaturation in patients with stable heart failure. Treatment with theophylline also improved the results of pulmonary-function tests. These effects occurred at therapeutic serum theophylline concentrations.
Effect of Theophylline on Periodic Breathing
Our patients had relatively severe periodic breathing during sleep, with an average apnea–hypopnea index of 37 during the placebo phase of the study, resulting in arterial oxyhemoglobin desaturation during approximately one quarter of the sleep time.
Theophylline has long been known to alleviate Cheyne–Stokes respiration and central apnea in premature infants14 and adults,15 although to our knowledge, no controlled studies have been reported. In an earlier study,4 using polysomnography, we reported that theophylline improved periodic breathing during sleep in three patients with heart failure and left ventricular systolic dysfunction. The present study shows that, as compared with placebo, theophylline resulted in a 51 percent reduction in the apnea–hypopnea index, mostly because of a reduction in the number of episodes of central apnea. The number of episodes of obstructive apnea was not significantly changed by theophylline therapy, confirming a previous finding16,17 and suggesting that our identification and classification of episodes of sleep apnea were probably correct.
While receiving theophylline, the patients had an arterial oxyhemoglobin saturation below 90 percent for only 6 percent of their total sleep time (as compared with 23 percent while they were receiving placebo). Nocturnal arterial oxyhemoglobin desaturation reduces survival among patients with chronic obstructive pulmonary disease, and survival is improved considerably with the administration of oxygen.18 It is therefore very likely that the treatment of marked arterial oxyhemoglobin desaturation in patients with heart failure also improves survival. Studies of long-term treatment involving large groups of patients are needed to establish the effect of theophylline therapy on survival.
The way in which theophylline improves central apnea remains unclear. Theophylline is a phosphodiesterase inhibitor, but its inhibitory action does not occur at the serum concentration (about 11 μg per milliliter) reached in our patients.19 At therapeutic serum concentrations, however, theophylline competes with adenosine at some of its receptor sites.19 In the central nervous system, adenosine is a respiratory depressant, and theophylline stimulates respiration by competing with adenosine.20-22 It is therefore conceivable that an increase in ventilation as a result of treatment with theophylline11,20-22 results in a decreased number of episodes of central apnea during sleep.23 Larger studies with appropriate measurements are needed to confirm this possibility.
Effect of Theophylline on the Characteristics of Sleep
The effects of theophylline on the stages of sleep, sleep efficiency, and the number of electroencephalographic arousals have been variable and controversial.17,24,25 We found that in patients with heart failure, in spite of the reduction in periodic breathing and associated arousals, the stages of sleep and the total number of arousals did not change significantly with theophylline therapy — findings that may have important implications for daytime functioning. However, the criteria for identifying an arousal vary among sleep laboratories, and a clinically relevant arousal has not yet been defined.
Effect of Theophylline on Pulmonary Function
Another interesting observation in our study was the improvement in the results of spirometric lung-function tests during treatment with theophylline. Our patients did not have obvious obstructive airway defects, and the ratio of the forced expiratory volume in one second to the forced vital capacity did not change significantly during the administration of theophylline. Furthermore, total lung capacity increased slightly during theophylline therapy. Theophylline thus improved the restrictive lung defect associated with heart failure.
The changes in the results of spirometric lung-function tests during treatment with theophylline were probably not related to changes in muscle strength, since the maximal inspiratory and expiratory pressures did not change significantly. This finding is consistent with our previous findings in normal persons.11
Effect of Theophylline on Cardiac Function
A limited number of controlled studies suggest that theophylline may improve the cardiac output8 and ventricular ejection fraction9 because of a positive inotropic effect. An increase in the cardiac output may explain, at least in part, the reduction in the number of episodes of central sleep apnea.1 The left and right ventricular ejection fractions, however, did not change significantly with theophylline therapy, although systematic hemodynamic studies are needed to address this question.
The prevalence of ventricular arrhythmias did not change significantly with the administration of theophylline. Only one patient had a supraventricular arrhythmia, which may or may not have been due to the drug. Theophylline thus appeared to be safe for the treatment of sleep apnea in our patients with heart failure.
Alternative Treatments
Several alternative treatments are available for periodic breathing in patients with heart failure.1 Continuous positive airway pressure has had variable success3,4,26 and should be used if there is obstructive apnea (e.g., in obese patients) or if the left ventricular end-diastolic pressure is increased.3,27 This treatment may increase the number of episodes of central apnea28 and may reduce the cardiac output, however, even in some patients with elevated left ventricular end-diastolic pressure.29 In addition, compliance with the use of the appliance is variable. The administration of nasal oxygen is effective and is the safest therapeutic approach.30 It is somewhat inconvenient, however, and patients may inadvertently remove the nasal cannula during sleep. On the basis of our findings, theophylline may be a reasonable alternative approach.
Supported by Merit Review grants from the Department of Veterans Affairs.
Source Information
From the Pulmonary Section (S.J., T.J.P., J.D.L.), the Cardiology Section (L.W., P.L.), and the Medical Service (G.A.R.), Veterans Affairs Medical Center and the University of Cincinnati College of Medicine — both in Cincinnati.
Address reprint requests to Dr. Javaheri at the Sleep Disorders Laboratory, Pulmonary Section (111F), VA Medical Center, 3200 Vine St., Cincinnati, OH 45220.
- References
References
1
Yamashiro Y ,Kryger MH . Sleep in heart failure. Sleep 1993;16:513-523
Web of Science | Medline2
Hanly PJ ,Millar TW ,Steljes DG ,Baert R ,Frais MA ,Kryger MH . Respiration and abnormal sleep in patients with congestive heart failure. Chest 1989;96:480-488
CrossRef | Web of Science | Medline3
Takasaki Y ,Orr D ,Popkin J ,Rutherford R ,Liu P ,Bradley TD . Effect of nasal continuous positive airway pressure on sleep apnea in congestive heart failure. Am Rev Respir Dis 1989;140:1578-1584
CrossRef | Web of Science | Medline4
Dowdell WT ,Javaheri S ,McGinnis W . Cheyne-Stokes respiration presenting as sleep apnea syndrome: clinical and polysomnographic features. Am Rev Respir Dis 1990;141:871-879
Web of Science | Medline5
Javaheri S ,Parker TJ ,Wexler L , et al. Occult sleep-disordered breathing in stable congestive heart failure. Ann Intern Med 1995;122:487-492[Erratum, Ann Intern Med 1995;123:77.]
Web of Science | Medline6
Javaheri S ,Colangelo G ,Lacey W ,Gartside PS . Chronic hypercapnia in obstructive sleep apnea-hypoapnea syndrome. Sleep 1994;17:416-423
Web of Science | Medline7
EEG arousals: scoring rules and examples: a preliminary report from the sleep disorders Atlas Task Force of the American Sleep Disorders Association
Medline8
Ogilvie RI ,Fernandez PG ,Winsberg F . Cardiovascular response to increasing theophylline concentrations. Eur J Clin Pharmacol 1977;12:409-414
CrossRef | Web of Science | Medline9
Matthay RA ,Berger HJ ,Davies R ,Loke J ,Gottschalk A ,Zaret BL . Improvement in cardiac performance by oral long-acting theophylline in chronic obstructive pulmonary disease. Am Heart J 1982;104:1022-1026
CrossRef | Web of Science | Medline10
Javaheri S ,Bosken CH ,Lim SP ,Dohn MN ,Greene NB ,Baughman RP . Effects of hypohydration on lung functions in humans. Am Rev Respir Dis 1987;135:597-599
Web of Science | Medline11
Javaheri S ,Guerra L . Lung function, hypoxic and hypercapnic ventilatory responses, and respiratory muscle strength in normal subjects taking oral theophylline. Thorax 1990;45:743-747
CrossRef | Web of Science | Medline12
Javaheri S ,Guerra L . Effects of domperidone and medroxyprogesterone acetate on ventilation in man. Respir Physiol 1990;81:359-370
CrossRef | Medline13
SAS/STAT users guide, version 6.03. Cary, N.C.: SAS Institute, 1988.
14
Gerhardt T ,McCarthy J ,Bancalari E . Aminophylline therapy for idiopathic apnea in premature infants: effects on lung function. Pediatrics 1978;62:801-804
Web of Science | Medline15
Dowell AR ,Heyman A ,Sieker HO ,Tripathy K . Effect of aminophylline on respiratory-center sensitivity in Cheyne-Stokes respiration and in pulmonary emphysema. N Engl J Med 1965;273:1447-1453
Full Text | Web of Science | Medline16
Guilleminault C ,Hayes B . Naloxone, theophylline, bromocriptine, and obstructive sleep apnea: negative results. Bull Eur Physiopathol Respir 1983;19:632-634
Medline17
Espinoza H ,Antic R ,Thornton AT ,McEvoy RD . The effects of aminophylline on sleep and sleep-disordered breathing in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 1987;136:80-84
CrossRef | Web of Science | Medline18
Nocturnal Oxygen Therapy Trial Group
Web of Science | Medline19
Rall TW . Evolution of the mechanism of action of methylxanthines: from calcium mobilizers to antagonists of adenosine receptors. Pharmacologist 1982;24:277-28720
Eldridge FL ,Millhorn DE ,Kiley JP . Antagonism by theophylline of respiratory inhibition induced by adenosine. J Appl Physiol 1985;59:1428-1433
Web of Science | Medline21
Javaheri S ,Teppema LJ ,Evers JAM . Effects of aminophylline on hypoxemia-induced ventilatory depression in the cat. J Appl Physiol 1988;64:1837-1843
Web of Science | Medline22
Javaheri S ,Evers JAM ,Teppema LJ . Increase in ventilation caused by aminophylline in the absence of changes in ventral medullary extracellular fluid pH and carbon dioxide tension. Thorax 1989;44:121-125
CrossRef | Web of Science | Medline23
Cherniack NS . Sleep apnea and its causes. J Clin Invest 1984;73:1501-1506
CrossRef | Web of Science | Medline24
Rhind GB ,Connaughton JJ ,McFie J ,Douglas NJ ,Flenley DC . Sustained release choline theophyllinate in nocturnal asthma. BMJ 1985;291:1605-1607
CrossRef | Web of Science | Medline25
Berry RB ,Desa MM ,Branum JP ,Light RW . Effect of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;143:245-250
Web of Science | Medline26
Buckle P ,Millar T ,Kryger M . The effect of short-term nasal CPAP on Cheyne-Stokes respiration in congestive heart failure. Chest 1992;102:31-35
CrossRef | Web of Science | Medline27
Bradley TD ,Holloway RM ,McLaughlin PR ,Ross BL ,Walters J ,Liu PP . Cardiac output response to continuous positive airway pressure in congestive heart failure. Am Rev Respir Dis 1992;145:377-382
Web of Science | Medline28
Guilleminault C ,Clerk A ,Labanowski M ,Simmons J ,Stoohs R . Cardiac failure and benzodiazepines. Sleep 1993;16:524-528
Web of Science | Medline29
Baratz DM ,Westbrook PR ,Shah PK ,Mohsenifar Z . Effect of nasal continuous positive airway pressure on cardiac output and oxygen de-livery in patients with congestive heart failure. Chest 1992;102:1397-1401
CrossRef | Web of Science | Medline30
Hanly PJ ,Millar TW ,Steljes DG ,Baert R ,Frais MA ,Kryger MH . The effect of oxygen on respiration and sleep in patients with congestive heart failure. Ann Intern Med 1989;111:777-782
Web of Science | Medline
- Citing Articles (78)
Citing Articles
1
Richard B. Berry. 2012. Central Sleep Apnea and Hypoventilation Syndromes. , 375-408.
CrossRef2
Kendra Becker, Charles Poon, Jennifer L. Martin. 2012. Sleep Disorders in Geriatric Patients. , 735-748.
CrossRef3
Winfried J. Randerath. 2012. Central and Mixed Sleep-Related Breathing Disorders. , 243-253.
CrossRef4
Thomas Brack, Winfried Randerath, Konrad E. Bloch. (2012) Cheyne-Stokes Respiration in Patients with Heart Failure: Prevalence, Causes, Consequences and Treatments. Respiration 83:2, 165-176
CrossRef5
Bhavneesh Sharma, David McSharry, Atul Malhotra. (2011) Sleep Disordered Breathing in Patients with Heart Failure: Pathophysiology and Management. Current Treatment Options in Cardiovascular Medicine 13:6, 506-516
CrossRef6
Richard S. T. Leung, Vikram R. Comondore, Clodagh M. Ryan, Daniel Stevens. (2011) Mechanisms of sleep-disordered breathing: causes and consequences. Pflügers Archiv - European Journal of Physiology
CrossRef7
Jan Hedner, Ludger Grote,, Ding Zou. 2011. Pharmacotherapeutic trials for sleep-disordered breathing. , 535-550.
CrossRef8
Ailiang Xie, Curtis A. Smith,, Jerome A. Dempsey. 2011. Sleep-induced breathing instability. , 53-81.
CrossRef9
Shigetake Sasayama. (2011) Treatment Options for Cheyne-Stokes Respiration and Heart Failure. Current Heart Failure Reports 8:3, 155-158
CrossRef10
Afshin Shirani, Sergio Paradiso, Mark Eric Dyken. (2011) The impact of atypical antipsychotic use on obstructive sleep apnea: A pilot study and literature review. Sleep Medicine 12:6, 591-597
CrossRef11
Andrew Wellman, David P. White. 2011. Central Sleep Apnea and Periodic Breathing. , 1140-1152.
CrossRef12
Shahrokh Javaheri. 2011. Heart Failure. , 1400-1415.
CrossRef13
Francoise J. Roux, Meir H. Kryger. (2010) Therapeutics for Sleep-disordered Breathing. Sleep Medicine Clinics 5:4, 647-657
CrossRef14
S. Javaheri. (2010) Positive Airway Pressure Treatment of Central Sleep Apnea with Emphasis on Heart Failure, Opioids, and Complex Sleep Apnea. Sleep Medicine Clinics 5:3, 407-417
CrossRef15
S. Javaheri. (2010) Central Sleep Apnea. Clinics in Chest Medicine 31:2, 235-248
CrossRef16
Bhavneesh Sharma, Robert Owens, Atul Malhotra. (2010) Sleep in Congestive Heart Failure. Medical Clinics of North America 94:3, 447-464
CrossRef17
Maria Klimathianaki, Eumorfia Kondili, Christina Alexopoulou, George Prinianakis, Dimitris Georgopoulos. (2010) Effect of propofol on breathing stability in adult ICU patients with brain damage. Respiratory Physiology & Neurobiology 171:3, 232-238
CrossRef18
Shuji Joho, Yoshitaka Oda, Tadakazu Hirai, Hiroshi Inoue. (2010) Impact of sleeping position on central sleep apnea/Cheyne–Stokes respiration in patients with heart failure. Sleep Medicine 11:2, 143-148
CrossRef19
Laila AlDabal, Ahmed S. BaHammam. (2010) Cheyne-Stokes Respiration in Patients with Heart Failure. Lung 188:1, 5-14
CrossRef20
Faisal Khan, Ribhi Hazin, Yuchi Han. (2010) Apneic Disorders Associated with Heart Failure: Pathophysiology and Clinical Management. Southern Medical Journal 103:1, 44-50
CrossRef21
T. Bitter, D. Horstkotte, O. Oldenburg. (2009) Therapie der Cheyne-Stokes-Atmung bei Herzinsuffizienz. Somnologie - Schlafforschung und Schlafmedizin 13:4, 204-210
CrossRef22
Safwan Badr. (2009) Central sleep apnea in patients with congestive heart failure. Heart Failure Reviews 14:3, 135-141
CrossRef23
Samuel L. Krachman, Gilbert E. D’Alonzo, Irene Permut, Wissam Chatila. (2009) Treatment of sleep disordered breathing in congestive heart failure. Heart Failure Reviews 14:3, 195-203
CrossRef24
Austin Chin Chwan Ng, Saul Benedict Freedman. (2009) Sleep disordered breathing in chronic heart failure. Heart Failure Reviews 14:2, 89-99
CrossRef25
Nishant B Jalandhara, Anil Patel, Rohit R Arora, Priyanka Jalandhara. (2009) Obstructive Sleep Apnea: A Cardiopulmonary Perspective and Medical Therapeutics. American Journal of Therapeutics 16:3, 257-263
CrossRef26
Matthew T. Naughton, Geraldo Lorenzi-Filho. (2009) Sleep in Heart Failure. Progress in Cardiovascular Diseases 51:4, 339-349
CrossRef27
Farouk Mookadam, Andrew D. Calvin, Virend K. Somers. (2008) Prevalence and management of central sleep apnea in heart failure patients. Current Heart Failure Reports 5:4, 233-237
CrossRef28
Shahrokh Javaheri. (2008) Sleep dysfunction in heart failure. Current Treatment Options in Neurology 10:5, 323-335
CrossRef29
T. Schäfer, M. E. Schläfke, M. Westhoff, H.-W. Duchna, T. Penzel, S. Scholle, M. Orth, . (2008) Zentrale Schlafapnoe –Pathophysiologie, Relevanz, Diagnostik und Therapie. Somnologie - Schlafforschung und Schlafmedizin 12:3, 190-204
CrossRef30
Virend K. Somers, David P. White, Raouf Amin, William T. Abraham, Fernando Costa, Antonio Culebras, Stephen Daniels, John S. Floras, Carl E. Hunt, Lyle J. Olson, Thomas G. Pickering, Richard Russell, Mary Woo, Terry Young. (2008) Sleep Apnea and Cardiovascular Disease. Journal of the American College of Cardiology 52:8, 686-717
CrossRef31
Matthew T. Naughton. (2008) Common Sleep Problems in ICU: Heart Failure and Sleep-Disordered Breathing Syndromes. Critical Care Clinics 24:3, 565-587
CrossRef32
Thomas E Vanhecke, Barry A Franklin, Steven C Ajluni, R Bart Sangal, Peter A McCullough. (2008) Cardiorespiratory fitness and sleep-related breathing disorders. Expert Review of Cardiovascular Therapy 6:5, 745-758
CrossRef33
Jonathan RL Schwartz, Rod J Hughes, Tom Roth. (2008) Pharmacologic therapy for sleep-related breathing disorders. Expert Review of Clinical Pharmacology 1:3, 441-455
CrossRef34
Jan Hedner, Ludger Grote, Ding Zou. (2008) Pharmacological treatment of sleep apnea: Current situation and future strategies. Sleep Medicine Reviews 12:1, 33-47
CrossRef35
Tomotaka Dohi, Takatoshi Kasai, Koji Narui, Sugao Ishiwata, Minoru Ohno, Tetsu Yamaguchi, Shin-ichi Momomura. (2008) Bi-Level Positive Airway Pressure Ventilation for Treating Heart Failure With Central Sleep Apnea That is Unresponsive to Continuous Positive Airway Pressure. Circulation Journal 72:7, 1100-1105
CrossRef36
Paul Gusbeth-Tatomir, Daniela Boisteanu, Anca Seica, Catalina Buga, Adrian Covic. (2007) Sleep disorders: a systematic review of an emerging major clinical issue in renal patients. International Urology and Nephrology 39:4, 1217-1226
CrossRef37
Shahrokh Javaheri, Rakesh Shukla, Haoyue Zeigler, Laura Wexler. (2007) Central Sleep Apnea, Right Ventricular Dysfunction, and Low Diastolic Blood Pressure Are Predictors of Mortality in Systolic Heart Failure. Journal of the American College of Cardiology 49:20, 2028-2034
CrossRef38
Timothy J. Barreiro, David J. Gemmel. (2007) Noninvasive Ventilation. Critical Care Clinics 23:2, 201-222
CrossRef39
Timothy A. Connolly, Amir Sharafkhaneh. (2007) Sleep-Related Breathing Disorder and Heart Disease—Central Sleep Apnea. Sleep Medicine Clinics 2:1, 107-117
CrossRef40
Jun-ichi Suzuki. (2007) Folia Pharmacologica Japonica 129:6, 427-431
CrossRef41
Raphael Heinzer, Amy Jordan, Atul Malhotra. 2006. Sleep Apnea Syndrome. .
CrossRef42
Jean-Louis Pépin, Nathalie Chouri-Pontarollo, Renaud Tamisier, Patrick Lévy. (2006) Cheyne–Stokes respiration with central sleep apnoea in chronic heart failure: Proposals for a diagnostic and therapeutic strategy. Sleep Medicine Reviews 10:1, 33-47
CrossRef43
Vivien C Abad, Christian Guilleminault. (2006) Pharmacological management of sleep apnoea. Expert Opinion on Pharmacotherapy 7:1, 11-23
CrossRef44
H. Worth. (2005) Behandlung von Atemstörungen im Schlaf. Der Pneumologe 2:5, 348-357
CrossRef45
Shahrokh Javaheri, Laura Wexler. (2005) Prevalence and treatment of breathing disorders during sleep in patients with heart failure. Current Treatment Options in Cardiovascular Medicine 7:4, 295-306
CrossRef46
Maritta M. Orth, Sandra Grootoonk, Hans-Werner Duchna, Justus de Zeeuw, Jörg W. Walther, Torsten T. Bauer, Gerhard Schultze-Werninghaus, Kurt Rasche. (2005) Short-term effects of oral theophylline in addition to CPAP in mild to moderate OSAS. Respiratory Medicine 99:4, 471-476
CrossRef47
David P. White. 2005. Central Sleep Apnea. , 969-982.
CrossRef48
Takatoshi Kasai, Koji Narui, Tomotaka Dohi, Sugao Ishiwata, Kunihiko Yoshimura, Shin-Ichiro Nishiyama, Tetsu Yamaguchi, Shin-Ichi Momomura. (2005) Efficacy of Nasal Bi-Level Positive Airway Pressure in Congestive Heart Failure Patients With Cheyne - Stokes Respiration and Central Sleep Apnea. Circulation Journal 69:8, 913-921
CrossRef49
Shahrokh Javaheri. 2005. Heart Failure. , 1208-1217.
CrossRef50
Karl-Heinz Ruhle, Friedhart Raschke, Ingo Fietze, Winfried Randerath, Thomas Wessendorf, Holger Hein, . (2004) Titration und Therapie mittels Positiv-Druckatmung bei schlafbezogenen Atemstorungen (SBAS). Titration and Therapy by Positive Pressure Breathing in Sleep-Related Breathing Disorders (SRBD). Somnologie 8:3, 95-109
CrossRef51
STEPHANE GARRIGUE, PHILIPPE BORDIER, S. SERGE BAROLD, JACQUES CLEMENTY. (2004) Sleep Apnea:. A New Indication for Cardiac Pacing?. Pacing and Clinical Electrophysiology 27:2, 204-211
CrossRef52
Hans-Werner Duchna, Ludger Grote, Stefan Andreas, Richard Schulz, Thomas E. Wessendorf, Heinrich F. Becker, Peter Clarenbach, Ingo Fietze, Holger Hein, Ulrich Koehler, Andreas Nachtmann, Winfried Randerath, Kurt Rasche, Karl-Heinz Ruhle, Bernd Sanner, Harald Schafer, Richard Staats, Volker Topfer. (2003) Sleep-Disordered Breathing and Cardio- and Cerebrovascular Diseases: 2003 Update of Clinical Significance and Future Perspectives. Schlafbezogene Atmungsstorungen und kardio- und zerebrovaskulare Erkrankungen: Update 2003 der klinischen Bedeutung und zukunftiger Entwicklungen. Somnologie 7:3, 101-121
CrossRef53
Curtis A Smith, Hideaki Nakayama, Jerome A Dempsey. (2003) The essential role of carotid body chemoreceptors in sleep apnea. Canadian Journal of Physiology and Pharmacology 81:8, 774-779
CrossRef54
S Garrigue, P Bordier, J Clémenty. (2003) Apnées du sommeil et stimulation cardiaque : mécanismes d’action et perspectives. Annales de Cardiologie et d'Angéiologie 52:4, 239-245
CrossRef55
Paola A. Lanfranchi, Virend K. Somers. (2003) Sleep-disordered breathing in heart failure: characteristics and implications. Respiratory Physiology & Neurobiology 136:2-3, 153-165
CrossRef56
Shahrokh Javaheri. (2003) Heart failure and sleep apnea: emphasis on practical therapeutic options. Clinics in Chest Medicine 24:2, 207-222
CrossRef57
M. J. Morrell. (2003) Sleep and Breathing in Congestive Heart Failure. Clinical Pulmonary Medicine 10:3, 170-176
CrossRef58
(2002) Atrial Pacing in Sleep Apnea Syndrome. New England Journal of Medicine 347:6, 445-446
Full Text59
Felix SF Ram, Paul Jones, Jose Jardim, Aldemar A Castro, Álvaro N Atallah, Yves Lacasse, Roger Goldstein, Sonia Cendon, Toby J Lasserson. 2002. Oral theophylline for chronic obstructive pulmonary disease. .
CrossRef60
Felix SF Ram, David DM Brocklebank, John White, John J Wright, Paul Jones, Toby J Lasserson. 2002. Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta-2 agonist bronchodilators for non-acute asthma. .
CrossRef61
Stuart G. Lehrman, George P. Maguire. (2002) Positive Airway Pressure for the Failing Heart. Heart Disease61-62
CrossRef62
Garrigue, Stephane, Bordier, Philippe, Jaïs, Pierre, Shah, Dipen C., Hocini, Meleze, Raherison, Chantal, Tunon De Lara, Manuel, Haïssaguerre, Michel, Clementy, Jacques, . (2002) Benefit of Atrial Pacing in Sleep Apnea Syndrome. New England Journal of Medicine 346:6, 404-412
Full Text63
Ailiang Xie, James B. Skatrud, Jerome A. Dempsey. (2001) Effect of hypoxia on the hypopnoeic and apnoeic threshold for CO2 in sleeping humans. The Journal of Physiology 535:1, 269-278
CrossRef64
Vahid Mohsenin. (2001) Sleep-Related Breathing Disorders: Current Treatment Options. Clinical Pulmonary Medicine 8:2, 95-100
CrossRef65
Bernd M. Sanner, Martin Konermann, Claus Doberauer, Thomas Weiss, Walter Zidek. (2001) Sleep-disordered breathing in patients referred for angina evaluation-association with left ventricular dysfunction. Clinical Cardiology 24:2, 146-150
CrossRef66
Wee See Yap, John A. Fleetham. (2001) Central sleep apnea and hypoventilation syndrome. Current Treatment Options in Neurology 3:1, 51-55
CrossRef67
Ronald R. Grunstein, Jan Hedner, Ludger Grote. (2001) Treatment Options for Sleep Apnoea. Drugs 61:2, 237-251
CrossRef68
Olov Sandberg, Karl A. Franklin, G??sta Bucht, Yngve Gustafson. (2000) Influence of Drugs on Sleep Apnoea in Stroke Patients. Clinical Drug Investigation 19:6, 447-455
CrossRef69
(2000) Central Sleep Apnea and Heart Failure. New England Journal of Medicine 342:4, 293-294
Full Text70
Javaheri, Shahrokh, . (1999) A Mechanism of Central Sleep Apnea in Patients with Heart Failure. New England Journal of Medicine 341:13, 949-954
Full Text71
M REITE. (1998) SLEEP DISORDERS PRESENTING AS PSYCHIATRIC DISORDERS. Psychiatric Clinics of North America 21:3, 591-607
CrossRef72
. (1998) Het effect van theofylline op slaapapnoe bij hartfalen. Medisch-Farmaceutische Mededelingen 36:7, 140-141
CrossRef73
H. Hein, H. Magnussen. (1998) Wie steht es um die medikamentöse Therapie bei schlafbezogenen Atmungsstörungen?. Somnologie - Schlafforschung und Schlafmedizin 2:2, 77-88
CrossRef74
Robert Vassallo, James J. Lipsky. (1998) Theophylline: Recent Advances in the Understanding of Its Mode of Action and Uses in Clinical Practice. Mayo Clinic Proceedings 73:4, 346-354
CrossRef75
Samuel Krachman, Gerard J. Criner. (1998) HYPOVENTILATION SYNDROMES. Clinics in Chest Medicine 19:1, 139-155
CrossRef76
Matthew T. Naughton, T. Douglas Bradley. (1998) SLEEP APNEA IN CONGESTIVE HEART FAILURE. Clinics in Chest Medicine 19:1, 99-113
CrossRef77
Jay M. Meythaler. (1997) Rehabilitation of Guillain-Barré syndrome. Archives of Physical Medicine and Rehabilitation 78:8, 872-879
CrossRef78
(1997) Theophylline and Sleep-Disordered Breathing in Heart Failure. New England Journal of Medicine 336:5, 379-379
Full Text
- Letters
